CHRS · Coherus Oncology, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Coherus Oncology reported Q2 2026 LOQTORZI net revenue of $13.6M (up 15% sequentially) with rebounded demand and the highest new patient starts since launch, while reiterating full-year LOQTORZI revenue guidance of $57–$62M; clinical enrollment completed in HNSCC, CRC and HCC studies with emerging tagmokitug activity expected to be disclosed in October; however, $37.5M Udenica earnout milestones were not achieved in Q2 and net loss from continuing operations was $33.3M with cash declining to $105.3M.
- + LOQTORZI Q2 net revenue grew 15% sequentially to $13.6M with rebounded demand and highest new patient starts since launch
- + R&D and SG&A expenses declined year-over-year, extending six consecutive quarters of declining SG&A
- + Enrollment completed across multiple pipeline studies (HNSCC, CRC, HCC) with initial data readouts expected in 2H 2026 including October disclosure
- + Management stated cash and investments sufficient to fund operations through key 2026 and 2027 data readouts
- − $37.5M Udenica divestiture earnout milestones were not achieved in Q2
- − Emerging tagmokitug HNSCC data is preliminary, based on small subsets and not yet formally cleaned, subject to change
- − Casdozokitug HCC Phase 2 data maturation delayed to Q4 2026 with only ~50 of 72 patients having had three scans
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CHRS
this stock
Coherus Oncology, Inc.
|
$180.77M | -14.8% | -100.0% | — | 14.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CHRS | -4.0% | -11.7% | -26.7% | -10.4% | -14.8% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -3.3% | -11.8% | -38.8% | -9.8% | -26.6% |